|
|
||||||||
1 From the Department of Ophthalmology, University of Rome "Tor Vergata"; the 2 Institute of Neurobiology, National Research Council, Rome; and the 3 Division of Ophthalmology, Hospital of Venice "SS. Giovanni e Paolo," Italy.
| Abstract |
|---|
|
|
|---|
METHODS. Expression of high-affinity NGF receptors, NGF-mRNA, and NGF protein was evaluated in human and rat normal corneas, in human and rat corneal epithelial cell cultures, in human corneal organ culture, and in the rat cornea after an experimental model of epithelial injury, by means of immunohistochemistry, in situ hybridization reverse transcriptionpolymerase chain reaction, and enzyme-linked immunosorbent assay.
RESULTS. The resultant data demonstrated that NGF is a constitutive molecule present and produced in normal human and rat corneas. In vitro human and rat corneal epithelial cells produce, store, and release NGF and also express high-affinity NGF receptors (TrkA). In human organ culture, epithelium, keratocytes, and endothelium have been shown to bind exogenous radiolabeled NGF, and the epithelial cells binding was increased after epithelium injury. In vivo, after rat corneal epithelial injury, a transient increase of corneal NGF levels was observed. Inhibition of endogenous NGF activity by neutralizing anti-NGF antibodies delayed the corneal epithelial healing rate, whereas exogenous administration of NGF accelerated healing.
CONCLUSIONS. Taken together, the above findings show that NGF plays an important role in corneal physiopathology and suggest that this neurotrophin may exert therapeutic action in wide-spectrum corneal diseases.
| Introduction |
|---|
|
|
|---|
We recently reported that the topical administration of nerve growth factor (NGF) in patients affected by neurotrophic corneal ulcer induces complete corneal recovery.6 This type of ocular disease is characterized by an impairment of corneal sensitivity innervation associated with a deficit of epithelial metabolism and vitality, leading to inadequate healing even after minor injury.7 8 9 In our study,6 we provided consistent evidence that topical NGF treatment restored stromal and epithelial integrity, but the types of cells receptive to NGF, as well as the mechanism(s) responsible for corneal healing, were not identified. Evidence that this clinical effect was mediated by the action of NGF on the epithelium was supported by the observations that human corneal epithelium express high-affinity NGF receptors (TrkA)10 and that in vitro NGF induce rabbit corneal epithelium to proliferate and differentiate.11 In the present study, the role of NGF, particularly at the cellular and molecular levels, in normal and epithelial injured human and rat corneas was investigated.
| Methods |
|---|
|
|
|---|
For animal experiments, 76 adult SpragueDawley male rats, weighing approximately 250 g, were obtained from Charles River Laboratories (Como, Italy). Rats were deeply anesthetized by intraperitoneal injection of ketamine (50 mg/kg) and xylazine (15 mg/kg). Animal care and procedures were conducted in conformity with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
NGF in Normal Human and Rat Corneas
To investigate the presence and production of NGF protein in human
(n = 6) and rat (n = 8) corneas, ELISA
was used to measure corneal NGF levels, RTPCR to detect NGF mRNA, and
ISH and immunohistochemistry to identify which cells expressed NGF mRNA
and NGF protein, respectively.
NGF in Normal and Injured Corneas In Vitro
The production, storage, and release of NGF from human and rat
epithelial cells were investigated. Epithelial cells were obtained by
mechanical removal from Eye Bank corneas (n = 4) and
rat corneas (n = 8). Cells were treated with trypsin
0.05% and EDTA 0.091% at 37°C for 3 hours, plated on lethally
irradiated 3T3-J2 cells (2.4 x
104/mm2), and then cultured
in 5% carbon dioxide in modified DulbeccoVogt Eagles and Hams
F-12 media (3:1 mixture).12
After 24 hours in culture,
epithelial cells were fixed in 4% paraformaldehyde.
Immunohistochemical analysis for NGF and TrkA and ISH for NGF mRNA were
then performed.13
14
Samples of culture medium were also
collected to measure NGF concentrations by ELISA.15
To identify the human corneal cells that were receptive to exogenous NGF, normal and injured human corneas were cultured in the presence of 1 µg/ml of radiolabeled NGF prepared as previously described.16 Eight human corneas were used; on four of them 3-mm-diameter epithelial lesions were created using a trephine incision and mechanical removal. Corneal discs were cultured in 60 ml of medium (minimum essential medium supplemented with 2% fetal calf serum, glutamine, HEPES buffer, antibiotics, and amphotericin B, all purchased from GIBCO SRL, Life Technologies, Milano, Italy) in conventional tissue culture bottles (Falcon; No. 3013E) and incubated at 37°C in a humidified atmosphere containing 5% carbon dioxide.17 After 24 hours in vitro, all corneas were fixed and evaluated by autoradiography.
In Vivo Animal Model of Corneal Epithelial Wound Healing
A total epithelial corneal debridement was performed in 30 animals
using n-heptanol and mechanical removal.18
NGF levels were
then measured at various time points post-injury: 2, 12, 24, 48, and
168 hours (n = 6 animals/time point).
All rats were maintained on a strict 12-hour light/dark cycle (6 AM on; 6 PM off) for at least 1 week before each experiment, and throughout the duration of the experiment, to synchronize their corneal epithelial circadian rhythms.19 Total corneal epithelial debridement was performed unilaterally. Briefly, a cotton swab saturated with n-heptanol was applied with moderate pressure to the cornea for 30 seconds. The corneal epithelium was then removed by means of a scraper, and the cornea was washed with 10 ml of physiological solution (0.9% NaCl). All wounds were made between 7 and 9 AM.
The corneal lesion was photographed immediately after the procedure and every 2 hours thereafter until the healing process was complete.20 The circumference of the wound margin, as projected onto the photograph, was traced on a digitizer, and the lesions area was calculated using a computer image analysis system (Videoplan, Kontron Elektronik, Germany). All measurements were counted in a masked fashion, and the size of de-epithelialized area was expressed as a percentage of the total corneal area.
Effects of Exogenous NGF or Anti-NGF Antibodies In Vivo
In two groups of animals (n = 12/group), the
corneal epithelium was removed as previously described. In the first
group, six animals were treated with topical administration of a 50
µl drop of NGF (stock solution 100 µg/ml of physiological solution)
every 2 hours, and the other six rabbits (controls) were treated with
physiological solution every 2 hours.6
Highly purified
active NGF form (coefficient of sedimentation = 2.5S) was
prepared from submaxillary glands of adult male mice, according to the
Bocchini and Angeletti method and further purified to remove all renin
activity as described.21
22
In the second group of animals, six rabbits were treated with topical administration of a 50 µl solution containing purified anti-NGF antibody (1 mg/ml of physiological solution) every 2 hours,23 and the other six animals (control) were treated with a 50 µl solution of nonspecific rabbit immunoglobulins at the same concentration every 2 hours.
The healing process was monitored by corneal photography every 2 hours from the time the lesion was induced. All animals were killed after the completion of corneal healing, and the corneas were histologically evaluated.
Immunohistochemistry and ISH
Human and rat corneas were fixed, cut into 10-µm-thick sections
with a cryostat, and processed for immunohistochemistry using an
affinity-purified NGF monoclonal antibody, which recognizes human and
rodent NGFs,24
or a specific rabbit polyclonal antibody
for TrkA (trk [763]; Santa Cruz, CA),10
which recognizes
high-affinity NGF receptors. According to the manufacturer, antibody
trk(763) specifically recognizes TrkA without cross-reacting with other
Trk receptors.25
26
To further assess specific binding of
NGF and TrkA, corneal sections were also exposed to nonspecific
purified immunoglobulins (IgGs).
ISH for NGF mRNA was performed on human and rat corneas as previously described.14 For hybridization, a 3'-end biotin-labeled oligonucleotide complementary to bases 886 to 930 of the rat NGF mRNA sequence,27 or to bases 703 to 742 of human NGF mRNA,28 was used at a final concentration of 30 ng/ml.
NGF and NGF mRNA Determination
NGF levels were measured in the human and rat corneas and in the
culture medium of human epithelial cells by a highly sensitive,
two-site ELISA with a sensitivity of 5 pg/ml, using anti-NGF antibodies
(Clone 27/21, Boehringer Mannheim, Mannheim, Germany), according to the
protocol previously described.15
To further verify whether the NGF was locally produced, the presence of its mRNA was also evaluated using a RTPCR procedure on human corneas. Total RNA was extracted by using the method of Chomczynski and Sacchi29 as modified in the TRIZOL kit (GIBCO SRL, Life Technologies, Milano, Italy), and RTPCR was performed as described previously.30 The PCR product, obtained using the sense 5'-CAGGACTCACAGGAGCAAGC-3' and anti-sense 5'-GCCTTCCTGCTGAGCACACA-3' primers, was a 349 baselong fragment corresponding to 511 to 889 of the human NGF gene.31
125I-NGF Incorporation in Human Corneal Organ
Culture
Human corneas were cultured in a medium containing 0.1 µg/ml of
125I-NGF. NGF was radioiodinated with
125I-Na (IMS30, 1 mCi; Amersham, Milan,
Italy) by the chloramine-T procedure and purified by Sephadex G-25
column chromatography.16
The specific activity was 1.0 to
1.5 Ci/mmol. To assess specific NGF binding to noninjured
(n = 2) and injured (n = 2)
corneas they were preincubated with a 100-fold excess of
non-radiolabeled (cold) NGF. After 24 hours in vitro, all corneas were
fixed overnight with 4% paraformaldehyde in phosphate buffer 100 mM,
pH 7.4. The tissues were subsequently placed in 30% buffered sucrose
solution for 24 hours. Sections of cornea were cut at a thickness of 15
µm for autoradiography. Slides were coated with the nuclear tracking
emulsion, Ilford K2 (Ilford Scientific Product, Knutsford, UK),
and, after 1 month of exposure, developed using a Kodak D19
developer.16
Sections were counterstained with
toluidine blue and observed under light microscope (Axiophot; Zeiss,
Oberkochen, Germany) at magnifications x40 and x100.
Statistical Analysis
ANOVA was calculated using the StatView package for Macintosh (SAS
Institute, Cary, NC). The effects of NGF or anti-NGF antibody (Ab-NGF)
on epithelial healing were analyzed by ANOVA considering the wound area
over time in the various treatment groups (saline versus NGF or
nonspecific IgGs versus Ab-NGF). Post-hoc comparisons within logical
sets of means were performed by the Tukey HSD test. Differences in NGF
concentration during the healing process were evaluated with the
nonparametric MannWhitney U test. P <
0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
These findings suggest that in normal corneas endogenous NGF is an essential factor for the trophism and integrity of the corneal epithelium. Moreover, the coexpression of NGF and its receptor on the same corneal cell suggests the presence of an autocrine and/or paracrine circuit that supports the survival and/or function of epithelial cells. A similar mechanism has been reported in neuronal and immune cells.32 33 34 35 36 A clinical study has demonstrated that NGF treatment accelerates the healing of corneal ulcers that had developed subsequent to dysfunction of corneal sensitivity innervation.6 It is well known that impairment of corneal sensitivity leads to decreased vitality and metabolism of the corneal epithelium.,7 8 9 37 with frequently associated epithelium rupture and delay or absence of spontaneously healing.
Corneal NGF levels were also shown to increase after corneal epithelial injury in the rat. It is possible that endogenous NGF plays an important role in epithelial healing by modulating the proliferation and differentiation of epithelial cells, a hypothesis also supported by results of in vitro studies in rabbit corneal epithelium.11 Evidence from various studies further strengthen this argument: in the present study, in vivo inhibition of endogenous NGF by Ab-NGF significantly delayed the epithelial healing process; animals with a targeted mutation for the NGF receptor develop ulcers and mutilation of the feet and corneal opacification38 39 ; and concentrations of NGF are decreased in ulcer tissue from patients affected by diabetes mellitus, leprosy, and nerve trauma.40 41
Both the previously reported clinical study and the findings of the present study have indicated that NGF was essential for the epithelial healing process and that its binding to corneal NGF receptor cells was a crucial event triggering its pharmacological activity. This hypothesis is consistent with the observation that in vitro human corneal cultures exposed to radiolabeled NGF demonstrated epithelial binding to exogenous NGF and that this binding was greatly enhanced in injured tissue. In addition, exogenous NGF treatment in vivo in rats with lesioned corneas significantly accelerated epithelial healing. Although these data clearly indicated the existence of a direct action of NGF on epithelial cells, the possibility of an indirect effect of NGF through the production and release of specific neuropeptides, which then acted as cell mediators capable of stimulating the healing process, cannot be excluded.4 5 42 43
A relevant observation in our in vivo studies was the presence of a mild anterior stromal opacification in 4 of 6 Ab-NGFtreated corneas, compared with 2 of 6 control eyes (both nonspecific IgG and saline-treated eyes) and 0 of 6 NGF-treated corneas. This finding suggests a role for NGF in epitheliumstroma communication leading to the induction of stromal healing and remodeling mechanisms, and/or the promotion of a rapid epithelial healing to avoid the onset of a stromal opacity. This attractive possibility needs to be explored in both in vitro and in vivo studies.
Cumulatively, our structural, biochemical, and molecular evidence support the previous clinical findings that NGF plays a crucial role in the corneal healing process.6 They also provide new insight into the pathophysiological mechanisms of NGF effects and into a potential therapeutic use of this neurotrophin in a wide spectrum of corneal injuries. Our working hypothesis is that NGF treatment promotes the healing process, avoiding the onset of the stromal remodeling mechanisms that lead to superficial stroma opacification in corneal disease.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication April 29, 1999; revised October 13, 1999; accepted November 8, 1999.
Commercial relationships policy: N.
Corresponding author: Luigi Aloe, Research Director, Institute of Neurobiology, National Research Council, Viale Marx 43/15, 00168 Rome, Italy. aloe{at}in.rm.cnr.it
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. D. Rios, E. Ghinelli, J. Gu, R. R. Hodges, and D. A. Dartt Role of Neurotrophins and Neurotrophin Receptors in Rat Conjunctival Goblet Cell Secretion and Proliferation Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1543 - 1551. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Gong, U. Pleyer, K. Vogt, I. Anegon, A. Flugel, H.-D. Volk, and T. Ritter Local Overexpression of Nerve Growth Factor in Rat Corneal Transplants Improves Allograft Survival Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1043 - 1052. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Shi, K. Y. Arai, W. Jin, Q. Weng, G. Watanabe, A. K. Suzuki, and K. Taya Expression of Nerve Growth Factor and Its Receptors NTRK1 and TNFRSF1B Is Regulated by Estrogen and Progesterone in the Uteri of Golden Hamsters Biol Reprod, May 1, 2006; 74(5): 850 - 856. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Lee, I. H. Ryu, E. K. Kim, J. E. Lee, S. Hong, and H. K. Lee Induced Expression of Insulin-like Growth Factor-1 by Amniotic Membrane-Conditioned Medium in Cultured Human Corneal Epithelial Cells. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 864 - 872. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lambiase, D. Merlo, C. Mollinari, P. Bonini, A. M. Rinaldi, M. D Amato, A. Micera, M. Coassin, P. Rama, S. Bonini, et al. Molecular basis for keratoconus: Lack of TrkA expression and its transcriptional repression by Sp3 PNAS, November 15, 2005; 102(46): 16795 - 16800. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Rihl, E Kruithof, C Barthel, F De Keyser, E M Veys, H Zeidler, D T Y Yu, J G Kuipers, and D Baeten Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment Ann Rheum Dis, November 1, 2005; 64(11): 1542 - 1549. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lambiase, P. Tirassa, A. Micera, L. Aloe, and S. Bonini Pharmacokinetics of Conjunctivally Applied Nerve Growth Factor in the Retina and Optic Nerve of Adult Rats Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3800 - 3806. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Esquenazi, H. E. P. Bazan, V. Bui, J. He, D. B. Kim, and N. G. Bazan Topical Combination of NGF and DHA Increases Rabbit Corneal Nerve Regeneration after Photorefractive Keratectomy Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3121 - 3127. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-J. Joo, K. R. Yuhan, J. Y. Hyon, H. Lai, S. Hose, D. Sinha, and T. P. O'Brien The Effect of Nerve Growth Factor on Corneal Sensitivity After Laser In Situ Keratomileusis Arch Ophthalmol, September 1, 2004; 122(9): 1338 - 1341. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Ripley, M. S. Chang, and D. M. Bader Bves Is Expressed in the Epithelial Components of the Retina, Lens, and Cornea Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2475 - 2483. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-Q. Tang, D. L. Tanelian, and G. M. Smith Semaphorin3A Inhibits Nerve Growth Factor-Induced Sprouting of Nociceptive Afferents in Adult Rat Spinal Cord J. Neurosci., January 28, 2004; 24(4): 819 - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
R B Vajpayee, N Mukerji, R Tandon, N Sharma, R M Pandey, N R Biswas, N Malhotra, and S A Melki Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects Br. J. Ophthalmol., November 1, 2003; 87(11): 1312 - 1316. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. S. J. Tuominen, Y. T. Konttinen, M. H. Vesaluoma, J. A. O. Moilanen, M. Helinto, and T. M. T. Tervo Corneal Innervation and Morphology in Primary Sjogren's Syndrome Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2545 - 2549. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Emanueli, M. B. Salis, A. Pinna, G. Graiani, L. Manni, and P. Madeddu Nerve Growth Factor Promotes Angiogenesis and Arteriogenesis in Ischemic Hindlimbs Circulation, October 22, 2002; 106(17): 2257 - 2262. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lambiase, S. Bonini, L. Manni, E. Ghinelli, P. Tirassa, P. Rama, and L. Aloe Intraocular Production and Release of Nerve Growth Factor after Iridectomy Invest. Ophthalmol. Vis. Sci., July 1, 2002; 43(7): 2334 - 2340. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Manni, T. Lundeberg, P. Tirassa, and L. Aloe Role of cholecystokinin-8 in nerve growth factor and nerve growth factor mRNA expression in carrageenan-induced joint inflammation in adult rats Rheumatology, July 1, 2002; 41(7): 787 - 792. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. You, S. Ebner, and F. E. Kruse Glial Cell-Derived Neurotrophic Factor (GDNF)-Induced Migration and Signal Transduction in Corneal Epithelial Cells Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2496 - 2504. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Teng, Z.-Y. Wang, and D. E. Bjorling Estrogen-induced proliferation of urothelial cells is modulated by nerve growth factor Am J Physiol Renal Physiol, June 1, 2002; 282(6): F1075 - F1083. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME |